Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00249990 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)
A Phase 2 study, sponsored by University of New Mexico.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT00249990 is a Phase 2 study that has completed, run by University of New Mexico. The registered enrollment target is 39 participants.
The verdict
NCT00249990, a Phase 2 study, has completed, sponsored by University of New Mexico.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purposes of this study are: 1.1 To determine the efficacy of liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) administered by aerosolization to patients with metastatic endometrial cancer. 1.2 To determine toxicity profile of L9NC administered by aerosolization for 5 consecutive days per week X 8 weeks, every 10 weeks. 1.3 To perform a pharmacology study of L9NC in the plasma and the lungs after aerosolization. A specific protocol will be written for this part.
Interventions
- DRUG 9-NC in aerosol reservoir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2003-04 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00249990
The ClinicalTrials.gov registry entry for NCT00249990 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of New Mexico, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 9-NC in aerosol reservoir is the first listed.
NCT00249990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00249990 about?
NCT00249990 is a clinical study titled "Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)". The purposes of this study are: 1.1 To determine the efficacy of liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) administered by aerosolization to patients with metastatic endometrial cancer. 1.2 To determine toxicity profile of L9NC administered by aerosolization for 5 consecutive days per week X 8 ...
What is the current status of trial NCT00249990?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2003-04. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00249990?
The interventions under investigation include: 9-NC in aerosol reservoir (DRUG).
Who is sponsoring clinical trial NCT00249990?
This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.